January 29, 2019 07:25 PM EST
People

Hit by tri­al set­back, Aslan slash­es staff and a study — hun­ker­ing down in wait for piv­otal da­ta

John Carroll

Editor & Founder

Two weeks af­ter re­port­ing the fail­ure of a key Phase II study of their lead drug, Aslan Phar­ma­ceu­ti­cals $ASLN is re­struc­tur­ing, slash­ing staff and shut­ter­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times